Paul Feuerstadt, MD, FACG, AGAF, discusses how testing for Clostridioides difficile is recommended for hospitalized patients or outpatients with new-onset, unexplained diarrhea who have risk factors ...

The panelist discusses how recurrent Clostridioides difficile infections represent a critical health care challenge, characterized by unmet needs in long-term prevention, microbiome restoration, and ...

A common practice for treating patients with gastrointestinal conditions has been revised by the American Gastroenterological Association, it announced Feb. 21. The group has expanded its ...

Please provide your email address to receive an email when new articles are posted on . Treatment-emergent adverse events occurred in 66.4% of patients who received Rebyota vs. 60.2% on placebo. Most ...

The researchers conducted a double-blind, randomized, placebo-controlled trial involving 2,655 adults in 30 countries around the world. The study participants were suffering from primary or recurrent ...

— Greg Vigna, M.D., J.D. SANTA BARBARA, CA, UNITED STATES, August 3, 2023/EINPresswire.com/ -- “Prolonged IV antibiotics are necessary for the treatment of Grade ...

Please provide your email address to receive an email when new articles are posted on . Allegretti presented data at Digestive Disease Week on safety outcomes and concomitant medication changes after ...

People with pneumonia who have experienced Clostridioides difficile (C. diff) infections may be able to reduce recurrences if they take doxycycline instead of the standard treatment. The study comes ...

An oral, investigational live biotherapeutic product containing eight strains of commensal Clostridia prevented recurrent Clostridioides difficile infections in a randomized, double-blind phase II ...